You are hereMay 19, 2017
What’s the Stem Cells Buzz this Week? – ASC-Promoted Tumorigenesis, Skull Repair with ASCs, Reviewing Wharton's Jelly Mesenchymal Stromal Cells, and BM-MSC Trial for Aplastic Anemia!
A roundup of some the recent stories in the ever-changing world of stem cells and regenerative medicine
How ASCs Promote Tumorigenesis
While breast reconstruction following tumor-related mastectomy often exploits the regenerative properties of adipose stem cells (ASCs), this stem cell type may also foster tumorigenesis through unknown mechanisms. In a new STEM CELLS article, researchers from the lab of Hongxin Deng (Sichuan University, P.R. China) discovered that the expression of CXCL1 and CXCL8 by human ASCs enhanced breast cancer angiogenesis. Has this new study uncovered a potentially druggable target for the treatment of breast cancer?
Long-term Results of ASC-mediated Skull Repair
Researchers from the lab of Tuomo Thesleff (Tampere University Hospital, Finland) have recently reported on the long-term follow-up of patients with skull injuries treated with autologous adipose-derived stem cells (ASCs) seeded on beta-tricalcium phosphate (betaTCP) granules. Their new STEM CELLS Translational Medicine study reported promising early results, although the 6-year follow-up in 5 patients found that conventional cranial repair methods and ASC-based treatment functioned to a similar degree. Therefore, the authors aim to reevaluate this strategy before moving forward.
Reviewing Wharton's Jelly Mesenchymal Stromal Cells
Many pre-clinical and clinical studies have assessed Wharton's Jelly mesenchymal stromal cells (WJ-MSCs) from the human umbilical cord as a possible therapeutically advantageous cell type. However, as noted by John E. Davies (University of Toronto, Ontario, Canada), “several aspects of this cell population have been under-appreciated”. This new review article proposes “a cord nomenclature-based robustly on anatomical/histological structure and developmental origins, within the context of providing a foundation for not only the much-needed methodological transparency in reporting of both basic and clinical studies, but also providing guidelines for the family banking sector”. See STEM CELLS Translational Medicine now for all the details.
Trialing Allogenic BM-MSCs for the Treatment of Aplastic Anemia
A new STEM CELLS Translational Medicine article from the lab of Yang Xiao (Hainan Cancer Hospital, PR China) reports the results of a phase II, non-comparative, multicenter study to assess the efficacy and safety of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) expanded in vitro for patients with aplastic anemia (AA) refractory to immunosuppressive therapy. Encouragingly, the authors report allogeneic BM-MSCs infusion to be feasible and effective. Great news!
So that’s a wrap for this week! Please let us know your views on all the stories we have covered here on the Stem Cells Buzz, and please let us know if we have missed anything interesting! Happy reading!